No Data
HC Wainwright & Co. Reiterates Buy on BioCardia, Maintains $4 Price Target
BioCardia Analyst Ratings
H.C. Wainwright Maintains BioCardia(BCDA.US) With Buy Rating, Cuts Target Price to $4
H.C. Wainwright analyst Joseph Pantginis maintains $BioCardia(BCDA.US)$ with a buy rating, and adjusts the target price from $60 to $4.According to TipRanks data, the analyst has a success rate of 37.
BioCardia Initiates Phase III Trial for Heart Failure Treatment
Express News | Patient Enrollment Commenced in Pivotal Phase 3 Trial of Cardiamp Cell Therapy for the Treatment of Ischemic Heart Failure
BioCardia (BCDA) Shares Climb In Extended Trading Session
No Data